LightNews LightNews
ndnissley.bsky.social
@ndnissley.bsky.social
6 followers 20 following 0 posts
Posts Replies Media Videos
Reposted
keiran-rowell.mastodon.social.ap.brid.gy
Gaze over this beautiful detail of the archeal ribosome, with the archea-only proteins in red. (The very core of the ribosome is thought to almost never change across all life)

Then have a look at the amazing H-bonding network of the catalytic peptide […]

[Original post on mastodon.social]
Fig. 1: Cryo-EM structures of the P. calidifontis ribosome. Ribosome proteins unique to archea are coloured in red. Fig. 2: Sequence variation in the P. calidifontis PTC. Extensive hydrogen bonding between the core catalytic RNA sites are shown, and vary from what is seen in other organisms. Fig. 4: Dri binding sites on the ribosome. The ribosome inhibiting protein is coloured in red
July 20, 2025 at 1:51 AM
Reposted
simanshu.bsky.social
BBO-10203 is currently being evaluated in the Phase 1 BREAKER-101 trial (NCT06625775) in patients with HER2+ and HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer. Read the BBOT press release here:
June 12, 2025 at 9:52 PM
Reposted
domespo.bsky.social
After many years of hard work by my colleagues at the Frederick National Laboratory and Bridge Bio Oncology Therapeutics, we finally have our first drug developed at the NCI RAS Initiaiive in clinical trials against KRAS--the driver of some very bad cancers. Details published this week:
Discovery of BBO-8520, a first-in-class direct and covalent dual inhibitor of GTP-bound (ON) and GDP-bound (OFF) KRASG12C
Abstract. Approved inhibitors of KRASG12C prevent oncogenic activation by sequestering the inactive, GDP-bound (OFF) form rather than directly binding and inhibiting the active, GTP-bound (ON) form. T...
aacrjournals.org
December 10, 2024 at 5:45 PM